Overview
Ceylon Hospitals operates the Durdans hospital, diagnostic and laboratory network, and related medical education businesses across Sri Lanka. The broad earnings picture improved sharply through the year to March, but the June quarter showed a less favourable mix: revenue continued to rise while operating profit contracted. The key issue is therefore whether the group can convert continued patient and diagnostic activity into sustained operating profit rather than relying on lower costs below the operating line.
Price performance
At LKR 61.00 on 2 October 2026, the voting share was up 38.4% over one year against a 1.9% fall in the ASPI, but it fell 4.7% over three months versus a 6.3% ASPI decline. The share therefore outperformed over the longer period but has moved broadly with the recent market retreat.
The price sat 35.8% below its 52-week high and 32.9% up from its low. Recent volatility was 44.8% below its own one-year norm and 20-day volume was 34.4% below the preceding 60-day level, meaning trading activity has been quieter than this share's own recent history.
The 1:4 subdivision effective 5 March 2026 increased every pre-existing share into four shares without changing the size of the business; adjusted returns are the relevant performance record. Over three years, there have been two falls of 15% or more, the deepest 39%, which has not yet recovered. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day, 409% of it.
Valuation
At 10.7 times earnings, the voting share asks for LKR 10.70 for each LKR 1 of trailing profit, while its 0.85 times P/B asks for 85 cents for each LKR 1 of net assets. Return on equity was 8.1% over the twelve months to June 2026, so the discount to book value is not being supported by a high current return on the equity base.
The P/E is more expensive than 72% of days since January 2019, and P/B is more expensive than 83% of days since January 2019. This contrasts with the market-wide moderately undervalued classification and shows that the current discount to book is less generous than the company's own longer trading record. The sector percentile is not supplied, although the 0.85 times P/B is below the healthcare peer median of 1.57 times.
The dividend yield is 1.8%, with the payout rising from LKR 0.50 in FY2024 to LKR 1.00 in FY2025 and LKR 1.10 in FY2026. A buyer at this price is relying on the latest June quarter for 29.7% of trailing EPS; at its year-ago net margin, the same price would stand on 10.6 times earnings rather than 10.7 times.
News and sentiment
Direct company coverage is thin, with no material articles recorded in the past 90 days. The notable filed item was the LKR 1.10 first interim dividend reported on 20 May 2026; its ex-date was 1 June 2026, so a buyer today does not receive it.
The March 2026 subdivision was completed on 5 March 2026. It changed the number of shares, not the group's assets, earnings power or total equity.
Financials
June-quarter revenue rose 8.5% year-on-year, but operating profit fell 6.6% and net profit increased only 4.7%. Sales therefore grew faster than profit, which means the additional hospital and diagnostic revenue produced less operating profit than a year earlier.
Gross margin was 56.9% versus 59.2% a year earlier, operating margin was 14.3% versus 16.6%, and net margin was 10.8% versus 11.2%. The gross margin was among the weakest June readings, ranking sixth of seven, while operating and net margins were middling for June at third and fourth of seven respectively. The LKR 104 million gap between operating and net profit was smaller than LKR 149 million a year earlier, helping net profit rise despite the operating decline.
For the audited year to March 2026, revenue rose 12.6% and net profit rose 44.9%, with annual net margin reaching 9.6%. Equity rose to LKR 12.9 billion from LKR 12.1 billion at June 2025. The balance sheet and per-share measures now use 167.6 million shares, the count in issue after the 1:4 split; older EPS and book-value-per-share figures on the former count are not directly comparable.
Risks
The largest operating risk is margin compression: the June operating margin fell 2.3 percentage points while revenue rose, so growing activity did not produce proportionate core profit. This matters more than the modest increase in net profit because operating profit is the earnings source before finance costs and tax.
Balance-sheet risk is limited but still relevant. Total debt was LKR 1.3 billion, equal to 11.2% of owners' equity, and operating profit covered the interest bill 8.07 times. The current ratio was 1.47 times, meaning the group had LKR 1.47 of short-term assets, including inventories and customer receivables, for each LKR 1 of bills due within a year. Operating cash flow was 1.07 times operating profit in the latest audited year, so the annual operating profit was converted into cash.
Minority shareholders received 9.6% of group profit in the latest audited year. Group net profit is therefore not wholly attributable to the ordinary shares being valued.
Outlook
As at 5 October 2026, the next event is the September 2026 interim filing, expected between 6 and 14 November. It will show whether the June pattern of revenue growth outpacing operating profit continued or reversed, and will supersede the currently available June-quarter figures.
The data does not provide a scheduled company-specific expansion, contract award or capital event beyond that filing. The broader environment includes an 8.75% policy rate, 8% September inflation and a weaker rupee, but these are market conditions rather than evidence of a direct effect on Ceylon Hospitals.